Stevanato Group (STVN) Q2 Earnings Match Estimates

Core Insights - Stevanato Group reported quarterly earnings of $0.10 per share, matching the Zacks Consensus Estimate, but down from $0.15 per share a year ago [1] - The company generated revenues of $279.44 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 1.43% and slightly up from $277.92 million year-over-year [2] - Stevanato shares have declined approximately 31.2% year-to-date, contrasting with the S&P 500's gain of 8.7% [3] Earnings Performance - Over the last four quarters, Stevanato has not surpassed consensus EPS estimates, with only one instance of exceeding revenue estimates [2] - The current consensus EPS estimate for the upcoming quarter is $0.15, with projected revenues of $312.49 million, and for the current fiscal year, the estimate is $0.53 on revenues of $1.22 billion [7] Market Outlook - The estimate revisions trend for Stevanato is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which Stevanato belongs, is ranked in the top 42% of over 250 Zacks industries, suggesting a potential for better performance compared to lower-ranked industries [8]